Intelligent Bio Solutions Inc. to Showcase Fingerprint Sweat PK Study at ADLM 2025 Clinical Lab Expo
TL;DR
Intelligent Bio Solutions Inc. (NASDAQ: INBS) offers a competitive edge with its non-invasive drug screening system, providing rapid, accurate results for workplace safety and compliance.
The Intelligent Fingerprinting Drug Screening System by INBS uses fingerprint sweat to accurately mirror drug levels in blood and saliva, validated by pharmacokinetic study data.
INBS's non-invasive testing solutions promote dignity and efficiency in drug screening, enhancing safety in workplaces and contributing to healthier communities worldwide.
Discover how INBS's innovative fingerprint sweat analysis is transforming drug testing, offering quick results without the need for invasive blood or saliva samples.
Found this article helpful?
Share it with your network and spread the knowledge!
Intelligent Bio Solutions Inc. (NASDAQ: INBS), a leader in non-invasive medical testing technologies, is set to present its groundbreaking pharmacokinetic (PK) study at the ADLM 2025 Clinical Lab Expo in Chicago. The study, which will be showcased by Daniel Brown, Head of Clinical Affairs, demonstrates the efficacy of the company's Intelligent Fingerprinting Drug Screening System in detecting codeine levels through fingerprint sweat, offering a promising alternative to traditional blood and saliva tests.
The ADLM 2025 Clinical Lab Expo, scheduled for July 27–31, serves as a pivotal platform for medical technology innovations. INBS's participation underscores the potential of its portable drug screening system to transform workplace, clinical, and justice settings by providing rapid, hygienic, and cost-effective testing solutions. The system's ability to deliver results in under ten minutes positions it as a critical tool for employers in safety-critical industries.
With over 450 accounts across 24 countries, INBS continues to expand its global footprint, reinforcing its commitment to advancing dignified and efficient testing methods. The company's technology, which screens for a range of substances including opiates, cocaine, methamphetamine, and cannabis, represents a significant leap forward in drug detection and monitoring.
The implications of INBS's study are far-reaching, offering a glimpse into the future of non-invasive diagnostic tools. By validating the correlation between fingerprint sweat and traditional testing methods, INBS not only enhances the credibility of its technology but also opens the door to broader applications in medical and forensic fields. This development is particularly relevant in today's fast-paced world, where the demand for quick and reliable testing solutions is ever-increasing.
For further details on Intelligent Bio Solutions Inc. and its innovative testing solutions, visit https://ibn.fm/suGlJ. Additional information and updates about INBS can be found in the company's newsroom at https://ibn.fm/INBS.
Curated from InvestorBrandNetwork (IBN)
